BioSpace News Archive

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it will be presenting findings from two nonclinical studies at the upcoming American Association of Pharmaceutical Scientists 2019 PharmSci 360 conference taking place in San Antonio, Texas at the Henry B. Gonzalez Convention Center, November 3–6, 2019

Predictive Technology Group, Inc., a leader in the development of genetic and molecular diagnostics and companion therapeutics, announced that it has engaged with LifeSci Partners to increase awareness of the company’s brand and clinical programs.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2019 financial results and provide a corporate update before market open on Thursday, November 7, 2019.

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it will webcast an investor event with its executive management team on Friday, November 8, 2019 from 6:00-8:00 p.m. ET.

Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019 via press release, which will be available on the Company’s website at www.geron.com/investors

Catalyst Pharmaceuticals, Inc. announced that it will release third quarter 2019 financial result after market close on Tuesday, November 12, 2019.

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced a management presentation at the following upcoming investor conference in November:

HTG Molecular Diagnostics, Inc., a diagnostic company whose mission is to advance precision medicine, announced that it will report its financial results for the third quarter ended September 30, 2019 after the market close on Tuesday, November 12, 2019.

Quotient Limited, a commercial-stage diagnostics company, announced positive preliminary US field trial data on the Initial Serological Disease Screening Microarray.

Plenary and late-breaking presentations on Phase 3 DISCOVER-1 and DISCOVER-2 data in the investigational use of TREMFYA® (guselkumab) in Psoriatic Arthritis to be Presented